Recent advances in treating Philadelphia chromosome-positive acute lymphoblastic leukemia offer hope for long-term remission without transplant, highlighting TKI discontinuation's potential.
Elisabetta Abruzzese, MD, PhD
Advertisement
Elisabetta Abruzzese, MD, PhD, is in the Department of Hematology at S. Eugenio University, both in Rome, Italy.
Articles by Elisabetta Abruzzese, MD, PhD
Recent studies reveal promising outcomes for discontinuing TKI therapy in select patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, suggesting potential long-term remission.
Careful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.
Advertisement
Latest Updated Articles
Treating the Patient With CML Who Is Pregnant or Trying to Become PregnantPublished: September 19th 2024 | Updated:
Exploring Factors Supporting TKI Discontinuation in Patients With Ph+ ALLPublished: June 27th 2025 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
3
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
4
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
5
